Caris Life Sciences shares rise 3.50% premarket after Guardant Health's Shield-MCD test selected for NCI's Vanguard study.

jueves, 17 de julio de 2025, 6:00 am ET1 min de lectura
CAI--
Caris Life Sciences, Inc. rose 3.50% in premarket trading. The company's stock price increase is not directly related to the news event provided, which pertains to Guardant Health, Inc. and its involvement in the Vanguard-Studie of the NCI.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios